Haemonetics (HAE) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $116.16 -0.81%
Revenue Growth %: +5.6%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Revenue Growth %: +5.6%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $1.29, $0.02 better than the analyst estimate of $1.27. Revenue for the quarter came in at $346 million versus the consensus estimate of $337.04 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primis Financial (FRST) Misses Q3 EPS by 7c
- JPMorgan Reinstates Skydance Corporation (SKYD) at Neutral
- Barclays Starts SGHC Limited (SGHC) at Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
